Reagent for prostatic cancer diagnosis and prognostic immunohistochemical detection

Abstract

The invention belongs to the technical field of biological detection reagents, and particularly relates to a reagent for prostatic cancer diagnosis and prognostic immunohistochemical detection. The reagent is characterized in that an antibody specific to an EHD2 protein of a human is used as a primary antibody or a core antibody; a chemical marker containing fluorescein, enzyme, metal ions or isotope is used as a second general antibody; the expression quantity of a target antigen (peptide and protein) in histocyte and subcellular localization of the histocyte are detected under color developing action and the like; the EHD2 protein is a protein encoded by gene EHD2; the GeneBank international sequence number of the gene EHD2 is: NM_014601; the GeneBank international sequence number of the gene EHD2 encoded protein is: NP_055416. The invention also discloses application of an EHD2 antibody in preparation of prostatic cancer immunohistochemical detection reagents. As the EHD2 protein participates in multi-step regulation for receptor and cell membrane transshipment, and plays an important role in retaining substance transportation and signal conduction in various cells, the EHD2 protein is closely related to diseases such as tumor.

Description

technical field [0001] The invention belongs to the technical field of biological detection reagents, in particular to an immunohistochemical detection reagent for prostate cancer diagnosis and prognosis judgment. Background technique [0002] Prostate cancer is one of the common tumors that threaten men. In European and American countries, it is second only to lung cancer and ranks second in the cause of cancer death in men. Epidemiological data show that the incidence of prostate cancer has significant regional, racial, and age differences. A number of studies have also pointed out that the incidence of prostate cancer is related to living habits, diet culture, work pressure, androgen levels, and family medical history. China is in a low-incidence area of ​​prostate cancer, but in recent years, the incidence of prostate cancer in Chinese men has been on the rise, which is related to the aging of the population, the improvement of quality of life and the change of lifestyl...

AI Technical Summary

Problems solved by technology

[0010] In order to solve the current clinical discrimination of tumors mentioned in the background technology, it is mainly based on the routine morphological observation of tumor tissues and tumor cells at the histopathological level, which is greatly affected by human factors such as the experience of pathologists, and lacks a deeper level. For the problem of molecular basis related to individual pathogenic factors of patients, the present invention discloses an immunohistochemical detection reagent for prostate cancer diagnosis and prognosis judgment

Images